Cancer immunotherapy using genetically modified immune cells

Adoptive transfer of ex vivo expanded autologous T cells genetically engineered to express a T cell receptor (TCR) or a chimeric antigen receptor (CAR) specific for a tumor antigen can induce durable clinical responses in many patients with cancers. However, there is some issues associated with 1) time to manufacture T cells, 2) cost to generate one product for individual patients, and 3) functional heterogeneity of the products. To overcome these issues, an immune cell platform broadly applicable for cancer immunotherapy is currently being developed as an off-the-shelf cellular therapeutic.